Debt to Assets Ratio: 9.60%
Is the debt to assets ratio high or low?
The debt to assets ratio of 9.60% is 43% below its 5-year average of 16.83%, near the low end of its 5-year range (9.60%–29.05%).
As of Friday, June 26, 2026. 9.59% below its 12-month average of 10.62%.
RMD Debt to Assets Ratio
Reported quarterly debt to assets ratio; no daily interpolation.
RMD Average Debt to Assets Ratio Chart
RMD Current vs Average Debt to Assets Ratio Chart
RMD Debt to Assets Ratio Metrics
DEBT TO ASSETS RATIO
9.60%
DEBT TO ASSETS RATIO AVG TTM
10.62%
DEBT TO ASSETS RATIO AVG 3Y
15.22%
DEBT TO ASSETS RATIO AVG 5Y
16.83%
DEBT TO ASSETS RATIO AVG 10Y
22.36%
DEBT TO ASSETS RATIO AVG 15Y
19.55%
DEBT TO ASSETS RATIO AVG 20Y
17.10%
CURRENT VS TTM AVG
-9.59%
CURRENT VS 3Y AVG
-36.94%
CURRENT VS 5Y AVG
-42.96%
CURRENT VS 10Y AVG
-57.07%
CURRENT VS 15Y AVG
-50.90%
CURRENT VS 20Y AVG
-43.88%
RMD Competitors' Debt to Assets Ratio
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ResMed Inc. (RMD) | $28.93B | 9.60% | 10.62% | 15.22% | 16.83% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 0.01% | N/A | N/A | N/A |
| DexCom, Inc. (DXCM)vs › | $26.76B | 0.22% | N/A | N/A | N/A |
| Biogen Inc. (BIIB)vs › | $31.39B | 0.24% | N/A | N/A | N/A |
| Moderna, Inc. (MRNA)vs › | $26.35B | 0.16% | N/A | N/A | N/A |
| IQVIA Holdings Inc. (IQV)vs › | $31.80B | 0.54% | N/A | N/A | N/A |
| Zoetis Inc. (ZTS)vs › | $32.07B | 0.61% | N/A | N/A | N/A |
| Mettler-Toledo International Inc. (MTD)vs › | $25.44B | 0.63% | N/A | N/A | N/A |
| Centene Corp. (CNC)vs › | $32.45B | 0.24% | N/A | N/A | N/A |
| Medline Inc. (MDLN)vs › | $32.87B | 0.33% | N/A | N/A | N/A |
Leverage Ratios Comparison
Debt/Assets
9.6%
Debt/Equity
0.14
Current Ratio
3.44
Interest Coverage
133.7x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
- Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
- Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
- Both measure leverage but from different perspectives
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt to Assets Ratio Formula & Definition
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Debt to Assets Ratio FAQ
- What is the debt to assets ratio for ResMed Inc. (RMD)?
- The debt to assets ratio for RMD stock is 9.60%.
- Is ResMed Inc.'s debt to assets ratio high or low?
- The debt to assets ratio of 9.60% is 43% below its 5-year average of 16.83%, near the low end of its 5-year range (9.60%–29.05%).
- What is the TTM average debt to assets ratio for ResMed Inc. (RMD)?
- The TTM average debt to assets ratio for RMD stock is 10.62%.
- What is the 3Y average debt to assets ratio for ResMed Inc. (RMD)?
- The 3Y average debt to assets ratio for RMD stock is 15.22%.
- What is the 5Y average debt to assets ratio for ResMed Inc. (RMD)?
- The 5Y average debt to assets ratio for RMD stock is 16.83%.
- What is the 10Y average debt to assets ratio for ResMed Inc. (RMD)?
- The 10Y average debt to assets ratio for RMD stock is 22.36%.
- What is the 15Y average debt to assets ratio for ResMed Inc. (RMD)?
- The 15Y average debt to assets ratio for RMD stock is 19.55%.
- What is the 20Y average debt to assets ratio for ResMed Inc. (RMD)?
- The 20Y average debt to assets ratio for RMD stock is 17.10%.
RMD Debt to Assets Ratio History
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-03-31 | 9.60% |
| 2025-12-31 | 11.78% |
| 2025-09-30 | 10.19% |
| 2025-06-30 | 10.42% |
| 2025-03-31 | 11.10% |
| 2024-12-31 | 11.76% |
| 2024-09-30 | 11.77% |
| 2024-06-30 | 12.72% |
| 2024-03-31 | 17.13% |
| 2023-12-31 | 20.15% |
| 2023-09-30 | 22.19% |
| 2023-06-30 | 23.40% |
| 2023-03-31 | 25.68% |
| 2022-12-31 | 29.05% |
| 2022-09-30 | 17.97% |
| 2022-06-30 | 18.01% |
| 2022-03-31 | 16.96% |
| 2021-12-31 | 17.67% |
| 2021-09-30 | 20.09% |
| 2021-06-30 | 16.79% |
| 2021-03-31 | 18.95% |
| 2020-12-31 | 21.12% |
| 2020-09-30 | 25.73% |
| 2020-06-30 | 28.32% |
| 2020-03-31 | 33.41% |
| 2019-12-31 | 32.13% |
| 2019-09-30 | 31.43% |
| 2019-06-30 | 30.94% |
| 2019-03-31 | 32.59% |
| 2018-12-31 | 31.02% |
| 2018-09-30 | 17.27% |
| 2018-06-30 | 9.19% |
| 2018-03-31 | 22.92% |
| 2017-12-31 | 28.60% |
| 2017-09-30 | 29.20% |
| 2017-06-30 | 31.10% |
| 2017-03-31 | 34.14% |
| 2016-12-31 | 35.17% |
| 2016-09-30 | 35.31% |
| 2016-06-30 | 35.99% |
| 2016-03-31 | 17.82% |
| 2015-12-31 | 17.94% |
| 2015-09-30 | 22.20% |
| 2015-06-30 | 13.78% |
| 2015-03-31 | 20.22% |
| 2014-12-31 | 19.33% |
| 2014-09-30 | 16.27% |
| 2014-06-30 | 12.74% |
| 2014-03-31 | 16.74% |
| 2013-12-31 | 18.58% |
| 2013-09-30 | 15.45% |
| 2013-06-30 | 13.61% |
| 2013-03-31 | 14.35% |
| 2012-12-31 | 12.91% |
| 2012-09-30 | 11.84% |
| 2012-06-30 | 11.73% |
| 2012-03-31 | 11.08% |
| 2011-12-31 | 11.09% |
| 2011-09-30 | 6.93% |
| 2011-06-30 | 4.84% |
| 2011-03-31 | 4.09% |
| 2010-12-31 | 3.42% |
| 2010-09-30 | 5.23% |
| 2010-06-30 | 7.48% |
| 2010-03-31 | 8.39% |
| 2009-12-31 | 8.95% |
| 2009-09-30 | 10.08% |
| 2009-06-30 | 10.73% |
| 2009-03-31 | 12.04% |
| 2008-12-31 | 11.70% |
| 2008-09-30 | 11.23% |
| 2008-06-30 | 9.79% |
| 2008-03-31 | 9.68% |
| 2007-12-31 | 10.05% |
| 2007-09-30 | 9.00% |
| 2007-06-30 | 9.26% |
| 2007-03-31 | 9.61% |
| 2006-12-31 | 11.79% |
| 2006-09-30 | 11.67% |
| 2006-06-30 | 12.02% |
| 2006-03-31 | 10.73% |
| 2005-12-31 | 23.67% |
| 2005-09-30 | 22.60% |
| 2005-06-30 | 22.52% |
| 2005-03-31 | 16.80% |
| 2004-12-31 | 18.13% |
| 2004-09-30 | 20.04% |
| 2004-06-30 | 20.62% |
| 2004-03-31 | 20.92% |
| 2003-12-31 | 22.87% |
| 2003-09-30 | 23.27% |
| 2003-06-30 | 24.64% |
| 2003-03-31 | 26.95% |
| 2002-12-31 | 29.25% |
| 2002-09-30 | 31.40% |
| 2002-06-30 | 32.76% |
About ResMed Inc.
ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Michael J. Farrell